A SiftingSignal publication/ Edited by Simon Mathews, MD

The week in GI, filtered to what is worth knowing.

Every week, 200+ papers from 25+ top GI and medical journals, transparently scored and physician-vetted. The signal, not the noise.

This week, in numbers

Issue №19 · week of Nov 8, 2026See the trends →
Top journals this week: NEJM / Nat Rev Gastro Hep / Lancet GH / Hepatology
Selectivity
9.5%
22 in the issue of 231 screened
in the issue 22in depth 39held 6filtered out 164
90.5% of what published this week did not make the issue. That filter is the product. A further 39 cleared the bar and are carried in one line each, in full on the subspecialty pages.
How this week moves the standard
Changes practice 0
No paper this week forces an outright change to the standard. That is the usual, honest result.
Each paper is matched to the guideline that governs its question, then placed by how it moves it. 15 of the 22 cards in the issue are matched to a standard, and each of those quotes it with its source and review date. From issue 14, every match is independently re-checked, so this bar reads lower than in earlier issues. Click a segment to filter the issue.
The signal map
547291narrative reviewguideline →Clinical utilityEvidence strength
Each dot is a paper: evidence strength across, clinical utility up (what you can do with it, what rides on it, how many patients, how new), area = the journal's impact factor, colour = subspecialty. A dark ring marks a paper that refines or changes its standard of care. The vertical scale spans this week's cards and its numbers are the real scores out of 100. Click a dot to open its card.

What to know this week

the top-scored · the 5-minute version

target ADR ≥30% in women and ≥40% in men to cut PCCRC risk by 46%, plozasiran cut acute pancreatitis from 5 to 1 per 100 patient-years and lowered triglycerides about 80% in severe hypertriglyceridemia, and use elafibranor to normalize ALP in PBC patients with ALP >1-<1.67× ULN after UDCA failure.

The 22 in the issue this week, ranked by signal score. Each anchored to the relevant standard of care. All in full below; 39 more, read and scored the same way, in one line each at the foot of the issue.

Your subspecialty, the takeaways
IBD17Hepatology8Esophagus/Reflux3Pancreas/Biliary8Endoscopy8Motility7Colorectal10
Type

This week to know

the 7 strongest this week · each scored 0 to 100 on what it lets you do, who it touches, the stakes, and how well the evidence backs it
Endoscopy prospective cohort · n=172,875 · Nov 5, 2026 · Clin Gastro Hep · IF 16.2

Risk of post-colonoscopy colorectal cancer according to colonoscopy quality and polyp findings.

New evidencecolonoscopypolypectomyendoscopy qualitycolorectal cancer screening
Clinical takeawayEnsure adenoma detection rates (ADR) meet or exceed ≥30% in women and ≥40% in men to reduce PCCRC risk.
What it foundIncreasing ADR to ≥30% in women and ≥40% in men could prevent 46% of PCCRC cases (95%CI, 27-76%) compared to lower ADR thresholds.
ContextConfirms the critical role of ADR in PCCRC prevention and extends evidence by quantifying the joint impact of ADR and polyp findings, highlighting the importance of optimizing colonoscopy quality.
Measured against the standard of care· USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

General post-polypectomy surveillance still follows USMSTF 2020 (Gupta et al.), which has not been replaced: 1-2 tubular adenomas <10 mm, 7-10 years; 3-4 tubular adenomas <10 mm, 3-5 years; 5-10 tubular adenomas <10 mm, any adenoma ≥10 mm, or an adenoma with tubulovillous/villous histology or high-grade dysplasia, 3 years; >10 adenomas, 1 year with polyposis evaluation. For serrated polyps: 1-2 SSLs <10 mm, 5-10 years; 3-4 SSLs <10 mm or a hyperplastic polyp ≥10 mm, 3-5 years; an SSL ≥10 mm, an SSL with dysplasia, or a traditional serrated adenoma, 3 years. When findings are mixed, use the shortest interval indicated. Before applying an interval, confirm complete resection and adequate prep. Piecemeal resections get a site check, and malignant (T1) polyps go to a tumor-board pathway. Serrated polyposis syndrome (SPS) is now governed by a separate USMSTF consensus statement (Rex et al., published simultaneously in Gastroenterology, Am J Gastroenterol and GIE on 2026-09-30). It has 11 recommendations. Diagnose SPS with the 2019 WHO criteria, which count the size, cumulative lifetime number and location of serrated polyps. Until SPS is diagnosed, record the number, size and location of serrated polyps in every colonoscopy report. SPS colonoscopy should be done by endoscopists with documented adequate SSL detection, using high-definition white light with or without chromoendoscopy. Without concurrent CRC, endoscopy is preferred over surgery for primary management. If the polyp burden cannot be managed endoscopically, refer to an advanced endoscopic resection expert before surgery. Resect SSLs and hyperplastic polyps by cold snare, with submucosal injection for larger lesions. Do clearance colonoscopy at 3-6 months, then surveil every 1-2 years. Consider 3-year intervals if the burden is greatly reduced at surveillance. First-degree relatives start colonoscopy at age 40, or 10 years before the youngest CRC diagnosis in the family, or 5 years before the youngest SPS diagnosis, whichever comes first. SPS has no established genetic basis, so germline testing is recommended only when concurrent non-serrated polyps suggest a heritable syndrome. Lynch, FAP/AFAP and MAP criteria still trigger genetic evaluation.

USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement) · reviewed 2026-10-11 ↗
Chen Y … Song M · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Pancreas/Biliary rct · n=757 · Nov 5, 2026 · NEJM · IF 84.5

Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.

New therapyacute pancreatitisbiomarkerepidemiology
Clinical takeawayPhase 3 evidence (SHASTA-3 and SHASTA-4, 757 adults) that lowering triglycerides with plozasiran 25 mg every 3 months lowers acute pancreatitis risk; check its approved indication before prescribing.
What it foundPlozasiran reduced acute pancreatitis risk to 1 per 100 patient-years vs 5 per 100 patient-years with placebo (rate ratio 0.22, P=0.008) and lowered triglycerides by 79-81% at 12 months. Adverse events occurred in 73% of patients in both plozasiran and placebo groups.
ContextTwo identically designed placebo-controlled trials; the pancreatitis result comes from a pooled analysis of adjudicated events. Adverse events occurred in 73% with plozasiran and with placebo.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Watts GF … SHASTA-3 and SHASTA-4 Study Groups · New England Journal of Medicine · IF 84.5 · PubMed ↗Permalink
Hepatology rct · n=92 · Nov 5, 2026 · Hepatology · IF 18.0

Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial.

New therapyPBCbiomarkerbasic sciencetranslational
Clinical takeawayConsider elafibranor 80 mg as a second-line treatment for PBC patients with ALP >1-<1.67× ULN after incomplete response/intolerance to ursodeoxycholic acid, aiming for ALP normalization.
What it foundElafibranor achieved ALP normalization in 85.3% of PBC patients with ALP >1-<1.67× ULN vs 23.3% with placebo (treatment difference: 62.0%; 95% CI: 44.3, 79.7; p<0.0001).
ContextConfirms elafibranor's efficacy in achieving ALP normalization, a treatment goal associated with better complication-free survival, in PBC patients with suboptimal response to UDCA.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance

Decision at stakewhether to use elafibranor as a second-line therapy for PBC patients with ALP >1-<1.67× ULN

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.

AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance · reviewed 2026-10-25 ↗
Kowdley KV … ELSPIRE Trial Investigators’ Group · Hepatology · IF 18.0 · PubMed ↗Permalink
Hepatology guideline · Nov 6, 2026 · Hepatology · IF 18.0

AASLD EXPO: Diagnosis and management of hepatitis delta virus (HDV) infection.

New evidenceviral hepatitisguidelineepidemiology
Clinical takeawayScreen all HBsAg positive patients for HDV at least once with HDV antibody testing. Confirm active infection with HDV RNA testing in HDV antibody positive individuals. Perform non-invasive fibrosis testing and HCC surveillance every 6 months. Consider bulevirtide therapy or bulevirtide plus peg-IFN alfa-2a for adults with chronic HDV viremia and compensated liver disease.
What it foundAll HBsAg positive individuals should be screened for HDV with HDV antibody, and HDV RNA testing confirms active infection. Non-invasive fibrosis testing and HCC surveillance every 6 months are recommended for chronic HDV.
ContextConfirms current practice by emphasizing universal HDV screening in HBsAg positive individuals and reinforces bulevirtide and peg-IFN alfa-2a as treatment options for chronic HDV.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026

Decision at stakescreening and management of HDV infection in HBsAg positive individuals

… Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

The 2026 AASLD/IDSA guideline addresses six PICO questions only; it states explicitly that all other 2018 AASLD recommendations for CHB management remain applicable, and that screening/diagnosis were out of scope. Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. Preferred agents remain entecavir, TDF, or TAF. THE SIX 2026 RECOMMENDATIONS: (1) PMTCT, for pregnant persons with HBV DNA >200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD RECOMMENDS initiating TDF or TAF at gestational week 28 (STRONG recommendation, MODERATE certainty, the only strong recommendation in the guideline); TDF has a more extensive safety record in pregnancy than TAF. Implementation qualifiers: initiate immediately if care is first sought after week 28; initiate at week 16 if infant HBIG will be unavailable (with subsequent infant vaccination); consider earlier initiation when amniocentesis is anticipated (transmission risk is increased with HBV DNA >2,000,000 IU/mL) or when preterm labor risk is high; continue TDF/TAF if already on it, switch entecavir or other agents to TDF/TAF; if treatment was solely for perinatal prophylaxis it may be discontinued at delivery, with HBV DNA and ALT monitored every 1-3 months for up to 6 months for withdrawal flare and treatment reinitiated if ALT >=5x ULN; use TDF or TAF in breastfeeding persons requiring treatment. (2) HORIZONTAL TRANSMISSION, for HBsAg-positive viremic persons not meeting disease-specific treatment indications who are in high-risk scenarios for transmission to others, AASLD SUGGESTS a shared decision-making approach regarding antiviral treatment (CONDITIONAL, VERY LOW certainty). Qualifiers the guideline stresses: the decision weighs exposure risk and the vaccine/immunity status of contacts, favoring treatment if contacts are unvaccinated, vaccine-nonresponsive, immunocompromised, or of unknown vaccine status; persons requesting treatment for prevention may be prescribed it since risks may not be disclosed; explicitly, people with CHB must NOT be restricted in daily activities, contact sports, school, or professional training and must NOT be required to take antivirals because of transmission risk in those settings; routine contact, shared meals, and hugging are not transmission routes (avoid sharing toothbrushes/razors); most healthcare workers with CHB are NOT high-risk, but those performing SHEA Category III exposure-prone procedures may require antivirals (SHEA target HBV DNA <1000 IU/mL); neither CDC nor SHEA requires disclosure to patients or staff; anti-stigma framing is part of the recommendation. (3) IMMUNE-TOLERANT PHASE, defined as HBeAg-positive, HBV DNA >10^7 IU/mL, and normal ALT; AASLD SUGGESTS antiviral therapy for those over age 40 years, OR with significant liver inflammation (grade >=2) or fibrosis (>=F2) on biopsy or noninvasive tests (CONDITIONAL, VERY LOW certainty). For persons under age 40 who are interested in starting treatment earlier, AASLD suggests shared decision-making weighing risk factors and the benefits and risks of treatment. Accurate phase identification requires persistently normal ALT on >=2 measurements >=6 months apart, using ULN 35 U/L (males) and 25 U/L (females). (4) INDETERMINATE ('grey zone') PHASE, the HBeAg-negative indeterminate phase is defined as HBsAg-positive, HBeAg-negative persons whose ALT and/or HBV DNA fall outside the thresholds for HBeAg-negative immune-active CHB (ALT >2x ULN and HBV DNA >2,000 IU/mL) and outside those for inactive CHB (HBV DNA <2,000 IU/mL with normal ALT), comprising predominantly two subgroups, (I) normal (<ULN) or mildly elevated (<2x ULN) ALT with HBV DNA >=2,000 IU/mL, or (II) elevated ALT (>ULN) with HBV DNA <2,000 IU/mL, with ALT interpreted against ULN 35 U/L (males) and 25 U/L (females) and phase assigned on >=2 ALT and HBV DNA measurements over a 6-12 month period; in adults who are HBsAg-positive, HBeAg-negative, without cirrhosis and in the indeterminate phase so defined, AASLD SUGGESTS antiviral therapy using a shared decision-making approach assessing risks and benefits, and re-evaluating that decision at each follow-up visit if treatment has not been initiated (CONDITIONAL, VERY LOW certainty). Decision-relevant factors include fibrosis stage, age, and sex, e.g. age >40, male sex, and low-normal platelets (<180 k/mm3) favor treatment. (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). If a patient nonetheless has a strong desire to stop, shared decision-making applies and ALL of the following must be met: no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, encephalopathy, hepatorenal syndrome), HCC, or extrahepatic HBV complications; if HBeAg-positive at treatment start, HBeAg seroconversion to anti-HBe-positive for >=1 year with undetectable HBV DNA >=2 years; if HBeAg-negative at start, undetectable HBV DNA >=2 years; no HIV or HDV coinfection; quantitative HBsAg <100 IU/mL; and willingness to adhere to frequent monitoring. After stopping, monitor ALT and HBV DNA every 1-3 months for 6 months, then every 3 months for 6-12 months, then every 3-6 months. Restart antivirals IMMEDIATELY if HBV DNA >=10,000 IU/mL (4 log IU/mL) at any time regardless of ALT, OR ALT >=5x ULN regardless of HBV DNA, OR total bilirubin >2.5 mg/dL. (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. Rec 7: in HBV-HDV coinfection, surveil adults independent of cirrhosis status; in children, individualize because HCC risk in that population is unknown. Rec 8: in HBV-HIV coinfection, surveil men >=18 years and women >=40 years. Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. Where a person has more than one coinfection, the surveillance recommendation should follow the coinfection carrying the highest associated risk. The guideline notes that most of its recommendations rest on low or very low certainty evidence and that shared decision-making, not uniform policy, is the intended mode of application.

American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026 · reviewed 2026-07-23 ↗
Lim JK … Terrault NA · Hepatology · IF 18.0 · PubMed ↗Permalink
Colorectal rct · n=82 · Nov 6, 2026 · Am J Gastro · IF 9.8

3% Sucralfate-Containing Topical Formulation Versus 0.2% Topical Nitroglycerin for Chronic Anal Fissure: A Double-Blind Randomized Controlled Trial.

New evidencebasic sciencetranslationalepidemiology
Clinical takeawayConsider topical 3% sucralfate as an alternative to nitroglycerin for chronic anal fissure, applied twice daily, given its superior healing rates in this study.
What it foundTopical 3% sucralfate achieved 50% fissure healing at 2 weeks vs 23% with nitroglycerin (RR 2.22, 95% CI 1.16-4.26), and 79% vs 48% at 4 weeks (RR 1.65, 95% CI 1.15-2.38).
ContextThis study suggests sucralfate may be more effective than nitroglycerin for chronic anal fissure healing, but further evidence is needed to confirm its role in clinical practice.
Emergingsuggested applicable standard· American Society of Colon and Rectal Surgeons (ASCRS), "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula" (Gaertner WB, Burgess PL, Davids JS, et al.), Diseases of the Colon & Rectum 2022;65(8):964-985, doi:10.1097/DCR.0000000000002473

… Treat acute anorectal abscess promptly with incision and drainage (1C), placing the incision close to the anal verge to limit subsequent tract length and preserve the sphincter complex; packing is not required and unpacked wounds gave better resolution, less pain and faster healing in randomized trials. … The anal fistula plug and fibrin glue are relatively ineffective (1B, upgraded from 2B; contemporary healing 50% or less). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose anorectal abscess and fistula-in-ano clinically: a disease-specific history and physical examination assessing symptoms, relevant history, abscess and fistula location, and secondary cellulitis (1C), with digital rectal exam and anoscopy/proctoscopy as needed. Routine diagnostic imaging is NOT typically necessary (1B); reserve imaging for selected patients with occult abscess, recurrent or complex fistula, immunosuppression, or anorectal Crohn's disease (MRI sensitivity 97% vs 74% for endoanal ultrasound in complex fistula; combined accuracy approaches 100%). Treat acute anorectal abscess promptly with incision and drainage (1C), placing the incision close to the anal verge to limit subsequent tract length and preserve the sphincter complex; packing is not required and unpacked wounds gave better resolution, less pain and faster healing in randomized trials. Reserve antibiotics for abscess complicated by cellulitis, systemic signs of infection, or underlying immunosuppression (2B); routine antibiotics after uncomplicated drainage in healthy patients do not improve healing or reduce recurrence, and conversely immunosuppressed patients with low neutrophil counts and no fluctuance may initially be treated with antibiotics alone rather than drainage. Concomitant fistulotomy at the time of drainage may be performed in selected patients with a simple anal fistula (2B), balancing lower recurrence (RR 0.13 in a 479-patient meta-analysis) against a non-significant increase in continence disturbance. For simple fistula-in-ano with normal sphincter function, lay-open fistulotomy heals over 90% (1B); for low fistulas involving less than one third of the external sphincter the clinically significant incontinence risk is minimal, and marsupialization improves healing and reduces bleeding. Sphincter-preserving options: endorectal advancement flap (1B; 66% to 87% initial healing, but up to 35% mild-to-moderate incontinence) and, for transsphincteric tracts, ligation of the intersphincteric fistula tract (LIFT) (1B; 76% pooled success, 1.4% incontinence). A cutting seton may be used selectively for complex cryptoglandular fistula (2C, downgraded from 2B; reported incontinence ranges 0% to 67%). The anal fistula plug and fibrin glue are relatively ineffective (1B, upgraded from 2B; contemporary healing 50% or less). Endoscopic or laser closure techniques (VAAFT, FiLaC, OTSC) have reasonable short-term healing but unknown long-term healing and recurrence rates (2C). In Crohn's disease, where abscess and fistula arise from penetrating inflammation rather than cryptoglandular infection, management is multidisciplinary and a draining seton is typically useful and may be used for long-term disease control (1B, upgraded from 1C); Crohn's disease is a named risk factor for failure or recurrence of fistulotomy, advancement flap, LIFT, and plug.

American Society of Colon and Rectal Surgeons (ASCRS), "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula" (Gaertner WB, Burgess PL, Davids JS, et al.), Diseases of the Colon & Rectum 2022;65(8):964-985, doi:10.1097/DCR.0000000000002473 · reviewed 2026-07-19 ↗
Lohsiriwat V … Ovartchaiyapong P · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Colorectal meta analysis · n=1,763 · Nov 3, 2026 · Dis Colon Rectum · IF 3.5

Risk of Distant Metastasis and Oncologic Outcomes of Clinical Near-Complete Responders After Neoadjuvant Therapy in Rectal Cancer: A Meta-Analysis.

New evidencerectal cancermeta-analysis
Clinical takeawayWeigh the higher metastasis and regrowth risk when offering watch-and-wait to near-complete responders; this analysis compares response groups and does not test whether surgery improves outcomes.
What it foundNear-complete response after neoadjuvant therapy for rectal cancer is associated with higher risk of distant metastasis (16.8% vs 7.3%; RR 2.31) and local regrowth (32.8% vs 19.7%; RR 1.75) compared to complete clinical response.
ContextTen studies, 1,763 patients; definitions of near-complete response and reassessment timing varied.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Marcolin P … Messaris E · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Esophagus/Reflux prospective cohort · n=136 · Nov 3, 2026 · Aliment Pharm Ther · IF 6.7

Clinical Trial: Capsule Sponge as a Non-Endoscopic Monitoring Tool in Eosinophilic Oesophagitis-A Prospective Real-World Multicentre Study.

New evidenceeosinophilic esophagitishealth services
Clinical takeawayIn adults with EoE without strictures, capsule sponge may reduce repeat endoscopies for monitoring; with sensitivity 76.3% (NPV 87.0%), a negative result does not exclude active disease.
What it foundCapsule sponge (CS) showed 76.3% sensitivity, 89.5% specificity, and 84.8% overall accuracy (Cohen's κ = 0.67) for monitoring EoE activity compared to endoscopic biopsies.
ContextProspective real-world study at three NHS sites (136 patients, 164 paired episodes); 92.7% swallowed the sponge with adequate sampling and no complications occurred.
Measured against the standard of care· ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

ACG 2025 (GRADE) is still the governing guideline. The ASGE 2026 consensus Part 2 (modified Delphi, 28 statements at ≥80% agreement; not GRADE) adds endoscopic and pediatric detail without contradicting it. DIAGNOSIS: symptoms of esophageal dysfunction plus ≥15 eos/hpf after excluding other causes of esophageal eosinophilia. A PPI trial is not a diagnostic criterion (PPI-REE abandoned). Do the initial diagnostic EGD off PPI, topical steroid and dietary therapy (ACG key concept; ASGE consensus, which gives no washout duration). Initial assessment is a standard EGD, not a less-invasive modality, so that full biopsies and dilation are possible (ASGE). Take ≥6 esophageal biopsies from ≥2 levels in anyone with symptoms or endoscopic findings consistent with EoE, targeting visible lesions. In CHILDREN with suspected EoE, also biopsy the stomach and duodenum (ASGE). Use EREFS at every endoscopy and report a quantified peak eosinophil count (ACG strong/low; ASGE). TREATMENT (ACG): swallowed topical steroids STRONG/moderate; high-dose PPI CONDITIONAL/low; empiric elimination diet CONDITIONAL/low. Choose a single initial therapy by shared decision-making. Fluticasone or budesonide are both reasonable. Adult doses: PPI double the reflux dose (e.g., omeprazole 20 mg BID or 40 mg daily); budesonide 2-4 mg/day (BOS 2 mg BID); fluticasone 1,760 mcg/day divided. Pediatric doses: PPI 2 mg/kg/day; budesonide 1-2 mg/day; fluticasone 110-880 mcg/day. Allergy testing is not used to direct diets. A 1FED/2FED step-up diet with a dietitian is acceptable, with endoscopic and biopsy confirmation after each reintroduced food. Dupilumab is CONDITIONAL for PPI-nonresponsive patients aged ≥12 (moderate) and for ages 1-11 at ≥15 kg (low). Weight-band dosing: 15-<30 kg 200 mg q2w; 30-<40 kg 300 mg q2w; ≥40 kg 300 mg weekly. Recommendations AGAINST: omalizumab, cromolyn, montelukast. No recommendation for cendakimab, benralizumab, lirentelimab, mepolizumab or reslizumab. DILATION: an adjunct to anti-inflammatory therapy for strictures causing dysphagia (ACG conditional/low). Start low and go slow; target ≥16 mm in adults and adolescents over ≥1 session. In children, ASGE supports dilation of symptomatic strictures or a narrow-caliber esophagus regardless of disease activity, using the same start-low/go-slow approach. MAINTENANCE: continue effective therapy (ACG STRONG despite low evidence) at the lowest effective dose. MONITORING: judge response on symptoms, endoscopy and histology together, never symptoms alone. Assess response endoscopically at 8-12 weeks after starting a PPI or topical steroid. For diet, ACG says 8-12 weeks and ASGE says 6-8 weeks. For dupilumab or biologics, assess at 12-24 weeks (ASGE: up to 24 weeks). Allow appropriate washout or timing after any treatment change before the follow-up EGD (ASGE). Take monitoring biopsies from the most severe-appearing lesions (rings, furrows, exudates) (ASGE). Monitoring biopsies may be limited to the esophagus when prior gastric and duodenal biopsies were normal and nothing new suggests other pathology (ASGE). The histologic response threshold of <15 eos/hpf is a 'may consider' target, read alongside endoscopic and symptom findings. Shorten follow-up after complications. Care gaps of ≥2 years are associated with fibrostenosis. PEDIATRIC (ACG): esophagram for children with dysphagia to assess fibrostenotic disease; feeding therapy and dietitian for feeding dysfunction; growth, development and nutrition are treatment goals.

ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417) · reviewed 2026-10-11 ↗
Kumar R … Morris DL · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink

The read

the next 15, in full

IBD· 3

IBD retrospective · n=10,482 · Nov 7, 2026 · J of Crohn's and Colitis · IF 8.3

Risk of perianal penetrating complications among adult patients with non-penetrating Crohn's disease initiating advanced therapies: a retrospective cohort study.

New evidenceCrohn's diseaseperianal diseasebiologicsJAK inhibitors
Clinical takeawayWhen perianal complications are a concern in non-penetrating Crohn's disease, weigh this claims-data association favouring a TNF antagonist or ustekinumab over vedolizumab; it held in advanced-therapy-naive and previously exposed patients.
What it foundTNF antagonists (HR 0.56) and ustekinumab (HR 0.62) were associated with lower risk of perianal penetrating complications compared to vedolizumab in non-penetrating Crohn's disease, both in advanced-therapy-naive and prior AT exposure subgroups.
ContextRefines current practice by comparing advanced therapies for perianal complication risk in non-penetrating Crohn's disease, highlighting subgroups with prior AT exposure.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

… Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Hupé M … Singh S · Journal of Crohn's and Colitis · IF 8.3 · PubMed ↗Permalink
IBD systematic review · Nov 7, 2026 · J of Crohn's and Colitis · IF 8.3

ECCO Topical Review: Inflammatory Bowel Disease-Like Patterns of Drug Colitis with Practical Guidance and a Focus on Immune Checkpoint Inhibitor-Induced Enterocolitis.

Guideline / review
Clinical takeawayIn suspected ICI enterocolitis, grade by CTCAE, test stool for pathogens and calprotectin, and perform endoscopy with biopsies and imaging when indicated. Start corticosteroids (mild or microscopic disease may respond to budesonide or beclomethasone), escalate early to infliximab or vedolizumab if steroid-refractory or dependent, and consider ICI rechallenge after multidisciplinary review.
What it foundTwenty-three ECCO Current Practice Positions on drug-induced enterocolitis; drug colitis can show IBD-like, acute, microscopic, ischemic-type or mixed patterns, none pathognomonic.
ContextClose clinicopathological collaboration is needed because no histological pattern is pathognomonic; surgery is reserved for refractory or complicated cases.
Reinforcessuggested applicable standard· American Gastroenterological Association (AGA), "AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review" (Dougan M, Wang Y, Rubio-Tapia A, Lim JK), Gastroenterology 2021;160(4):1384-1393

… In grade 2 or higher colitis/diarrhea, early stool inflammatory markers (lactoferrin, calprotectin) may help stratify patients for endoscopy, and endoscopic confirmation of the diagnosis and severity should be considered before starting high-dose systemic glucocorticoids; abdominal imaging is reserved for dominant pain, fever, or bleeding and should not be done routinely for diarrhea alone. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For suspected ICI colitis, exclude infectious causes of diarrhea (including C. difficile) before treating. In grade 2 or higher colitis/diarrhea, early stool inflammatory markers (lactoferrin, calprotectin) may help stratify patients for endoscopy, and endoscopic confirmation of the diagnosis and severity should be considered before starting high-dose systemic glucocorticoids; abdominal imaging is reserved for dominant pain, fever, or bleeding and should not be done routinely for diarrhea alone. The AGA cautions that no validated severity index for ICI colitis exists and that symptoms correlate poorly with endoscopic, radiologic, and treatment-response severity, and that rapid progression over days can occur, particularly with ipilimumab. ICI colitis typically responds to high-dose systemic glucocorticoids at 0.5-2 mg/kg prednisone-equivalent daily tapered over 4-6 weeks (the AGA explicitly notes these doses and schedules have not been rigorously examined). If there is no improvement after 2-3 days, add infliximab or vedolizumab while continuing glucocorticoids; both are reasonable options for glucocorticoid-refractory colitis. Budesonide is ineffective as prophylaxis and is not a standard treatment for ICI colitis, it is reserved for ICI-associated microscopic colitis. Retreatment with immunotherapy is possible under select conditions. For hepatitis, obtain baseline liver chemistries (total bilirubin, alkaline phosphatase, AST, ALT) and HBV serologies before ICI; grade by CTCAE and manage as follows: grade 1 (AST/ALT 1-3x ULN or bilirubin 1-1.5x ULN), monitor liver chemistries 1-2 times weekly; grade 2 (AST/ALT >3-5x ULN or bilirubin >1.5-3x ULN), hold ICI until resolution to grade 1, and if symptomatic give prednisone 0.5-1.0 mg/kg/d or equivalent; grade 3 (AST/ALT >5-20x ULN or bilirubin >3-10x ULN), discontinue ICI and start methylprednisolone 1-2 mg/kg/d or equivalent; grade 4 (AST/ALT >20x ULN or bilirubin >10x ULN or hepatic decompensation), permanently discontinue ICI and start methylprednisolone 2 mg/kg/d. For ICI hepatitis that does not adequately improve after 3-5 days of high-dose glucocorticoids, escalate to a second-line immunosuppressant, mycophenolate mofetil (with azathioprine as an accepted alternative), while continuing glucocorticoids; infliximab is not recommended for ICI hepatitis because of its potential for hepatotoxicity. Evaluate all ICI-related liver-chemistry elevations for alternate etiologies (consider liver biopsy), and obtain biliary imaging when alkaline phosphatase and/or bilirubin are elevated.

American Gastroenterological Association (AGA), "AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review" (Dougan M, Wang Y, Rubio-Tapia A, Lim JK), Gastroenterology 2021;160(4):1384-1393 · reviewed 2026-07-23 ↗
Verstockt B … Feakins R · Journal of Crohn's and Colitis · IF 8.3 · PubMed ↗Permalink
IBD retrospective · n=145 · Nov 7, 2026 · J of Crohn's and Colitis · IF 8.3

Value of non-contrast magnetic resonance imaging for diagnosis of perianal fistulas in Crohn's disease.

New evidenceperianal diseaseCrohn's diseaseartificial intelligence
Clinical takeawayConsider NC-MRI as a reasonable alternative to CE-MRI for detecting and grading perianal fistulas in Crohn's disease patients who cannot receive contrast or for abbreviated exams, but CE-MRI remains superior for complex disease.
What it foundNC-MRI detected index fistulas in 115/145 patients (79%) vs 117/145 (81%) on CE-MRI, with 96% sensitivity and 93% specificity for index fistula detection.
ContextConfirms NC-MRI as a viable alternative to CE-MRI for initial fistula detection and grading, though CE-MRI has added value for assessing complex perianal disease, including secondary fistulas and tracts.
Refinessuggested applicable standard· American Society of Colon and Rectal Surgeons (ASCRS), "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula" (Gaertner WB, Burgess PL, Davids JS, et al.), Diseases of the Colon & Rectum 2022;65(8):964-985, doi:10.1097/DCR.0000000000002473

Decision at stakethe use of MRI for diagnosing perianal fistulas in Crohn's disease

… Routine diagnostic imaging is NOT typically necessary (1B); reserve imaging for selected patients with occult abscess, recurrent or complex fistula, immunosuppression, or anorectal Crohn's disease (MRI sensitivity 97% vs 74% for endoanal ultrasound in complex fistula; combined accuracy approaches 100%). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose anorectal abscess and fistula-in-ano clinically: a disease-specific history and physical examination assessing symptoms, relevant history, abscess and fistula location, and secondary cellulitis (1C), with digital rectal exam and anoscopy/proctoscopy as needed. Routine diagnostic imaging is NOT typically necessary (1B); reserve imaging for selected patients with occult abscess, recurrent or complex fistula, immunosuppression, or anorectal Crohn's disease (MRI sensitivity 97% vs 74% for endoanal ultrasound in complex fistula; combined accuracy approaches 100%). Treat acute anorectal abscess promptly with incision and drainage (1C), placing the incision close to the anal verge to limit subsequent tract length and preserve the sphincter complex; packing is not required and unpacked wounds gave better resolution, less pain and faster healing in randomized trials. Reserve antibiotics for abscess complicated by cellulitis, systemic signs of infection, or underlying immunosuppression (2B); routine antibiotics after uncomplicated drainage in healthy patients do not improve healing or reduce recurrence, and conversely immunosuppressed patients with low neutrophil counts and no fluctuance may initially be treated with antibiotics alone rather than drainage. Concomitant fistulotomy at the time of drainage may be performed in selected patients with a simple anal fistula (2B), balancing lower recurrence (RR 0.13 in a 479-patient meta-analysis) against a non-significant increase in continence disturbance. For simple fistula-in-ano with normal sphincter function, lay-open fistulotomy heals over 90% (1B); for low fistulas involving less than one third of the external sphincter the clinically significant incontinence risk is minimal, and marsupialization improves healing and reduces bleeding. Sphincter-preserving options: endorectal advancement flap (1B; 66% to 87% initial healing, but up to 35% mild-to-moderate incontinence) and, for transsphincteric tracts, ligation of the intersphincteric fistula tract (LIFT) (1B; 76% pooled success, 1.4% incontinence). A cutting seton may be used selectively for complex cryptoglandular fistula (2C, downgraded from 2B; reported incontinence ranges 0% to 67%). The anal fistula plug and fibrin glue are relatively ineffective (1B, upgraded from 2B; contemporary healing 50% or less). Endoscopic or laser closure techniques (VAAFT, FiLaC, OTSC) have reasonable short-term healing but unknown long-term healing and recurrence rates (2C). In Crohn's disease, where abscess and fistula arise from penetrating inflammation rather than cryptoglandular infection, management is multidisciplinary and a draining seton is typically useful and may be used for long-term disease control (1B, upgraded from 1C); Crohn's disease is a named risk factor for failure or recurrence of fistulotomy, advancement flap, LIFT, and plug.

American Society of Colon and Rectal Surgeons (ASCRS), "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula" (Gaertner WB, Burgess PL, Davids JS, et al.), Diseases of the Colon & Rectum 2022;65(8):964-985, doi:10.1097/DCR.0000000000002473 · reviewed 2026-07-19 ↗
Lewis S … Taouli B · Journal of Crohn's and Colitis · IF 8.3 · PubMed ↗Permalink

Hepatology· 3

Hepatology review · Nov 2, 2026 · Hepatology · IF 18.0

MRI-based biomarkers for risk stratification and assessment of treatment response in Metabolic dysfunction-associated Steatotic liver disease.

New evidencebiomarkerartificial intelligencecost-effectiveness
Clinical takeawayWhere MRI is available: MRI-PDFF thresholds of 6.4%, 17.4% and 22.1% grade steatosis, and a ≥30% relative fall is associated with histologic response; MRE-LS of 3.1 to 4.4 kPa corresponds to F2-F3 and ≥5 kPa to cirrhosis, with each 1-kPa rise associated with 43% higher decompensation risk.
What it foundMRI-PDFF thresholds of 6.4%, 17.4%, and 22.1% define steatosis grades ≥1, ≥2, and 3, and a ≥30% relative reduction predicts histologic response; MRE-LS of 3.1-4.4 kPa indicates F2-F3 fibrosis, ≥5 kPa cirrhosis, and each 1-kPa increase raises hepatic decompensation risk by 43%.
ContextRefines current practice by validating MRI-based biomarkers as accurate, non-invasive alternatives to liver biopsy for steatosis and fibrosis assessment in MASLD.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Mironova M … Loomba R · Hepatology · IF 18.0 · PubMed ↗Permalink
Hepatology prospective cohort · n=51 · Nov 1, 2026 · Dig Endosc · IF 5.2

EUS-PPG Measured Distal to the Thrombus: A Reliable Way to Detect the Pressure Gradient in Patients With Cirrhosis and Portal Vein Thrombosis.

New evidenceportal hypertensionvariceal bleedingbiomarker
Clinical takeawayEUS-guided Dis-PVT PPG shows promise as an investigational measure of portal hypertension in cirrhotic patients with PVT, particularly in those with a history of variceal bleeding, but further validation is needed before clinical use.
What it foundDis-PVT PPG ≥12 mmHg was associated with a higher incidence of red sign (OR=5.6) and bleeding history (OR=7.0) compared to those with lower PPG in cirrhotic patients with PVT.
ContextSuggests EUS-guided Dis-PVT PPG may offer an alternative to HVPG in PVT patients, though comparative accuracy remains to be established.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211.

Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. … Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. Everything else in the current entry (HCC surveillance, transplant referral, nutrition, vaccination, ascites/SBP/HE/HRS/ACLF management) belongs to the separate documents listed as supporting sources and must not be attributed to this guidance. Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L. Where spleen stiffness measurement is available, values below 21 kPa argue against CSPH and above 50 kPa argue for it. These non-invasive cutoffs are conditional probability thresholds, not universal diagnostic rules, and hold only when their derivation conditions are met. They were established in compensated advanced chronic liver disease of viral (treated or untreated HBV/HCV), alcohol-related, or non-obese (BMI under 30) MASLD etiology, and are not validated for and should not be applied to cholestatic (e.g. PBC, PSC), vascular, or other etiologies, in which different cutoffs apply. They also require a technically reliable liver stiffness measurement by vibration-controlled transient elastography, fasting, at least 10 valid acquisitions, and an IQR/median ratio below 30 percent, and are confounded by factors that raise liver stiffness independently of fibrosis, including ALT flares or acute hepatitis, extrahepatic cholestasis, hepatic congestion (right heart failure), and recent food intake; Baveno VII recommends confirming an LSM-based rule-in on a repeat measurement obtained on a separate day. The spleen stiffness cutoffs apply only to a dedicated 100 Hz spleen module, carry a higher technical failure rate, are machine-dependent, and are not interchangeable with values obtained using the standard 50 Hz liver probe. Where these population or acquisition conditions are not met, the numeric thresholds do not reliably classify CSPH, and HVPG measurement or endoscopy is required rather than a non-invasive determination. Preserve the gray zone: LSM 15 to 25 kPa without a qualifying platelet count is explicitly indeterminate (roughly 40 to 60 percent of cACLD patients) and calls for HVPG and/or endoscopy rather than assumption in either direction. Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. This is a treat-the-pressure strategy rather than a treat-the-varices one: because a patient already on NSBB for CSPH would not have management changed by the finding, screening endoscopy becomes unnecessary for most such patients. Screening EGD is still indicated where elastography is unavailable, technically difficult, or gives discordant results, and for patients who do not meet non-invasive criteria. Standard beta-blocker contraindications (severe asthma, advanced heart block, bradyarrhythmias) continue to apply. For varices needing treatment managed endoscopically, band ligation is repeated every 2 to 4 weeks until obliteration, with surveillance endoscopy at 6 months and annually thereafter. Gastric/cardiofundal varices are treated with cyanoacrylate injection or EUS-guided coil embolization rather than banding, with hepatology involvement. In acute variceal hemorrhage, consider preemptive (early) TIPS within 24 to 72 hours in high-risk patients: Child-Turcotte-Pugh class B with score above 7 and active bleeding at endoscopy despite vasoactive therapy, or CTP class C with score 10 to 13. Keep the document's own qualifier: there is no established universal MELD or CTP cutoff at which TIPS is mandatory, and the decision is case-by-case with hepatology consultation. Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. Verification note: the Hepatology full text is paywalled (402/403 on direct fetch). Document identity, title, year, volume, pages and authorship were confirmed via Crossref and PubMed metadata; the numeric thresholds above were corroborated from two independent peer-reviewed commentaries on this specific guidance and match the Baveno VII rule-of-five, but were not read verbatim from the primary PDF. A human should confirm the exact guidance-statement wording against the full text before this entry is treated as quotation-grade.

American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211. · reviewed 2026-07-23 ↗
Wei W … Xue M · Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society · IF 5.2 · PubMed ↗Permalink
Hepatology systematic review · Nov 4, 2026 · Lancet GH · IF 39.1

Global, regional, and national burden of gallbladder and biliary diseases in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Epidemiologyepidemiologysystematic reviewhealth services
Clinical takeawayNo clinical action yet: this is an epidemiological study quantifying global burden and trends, not a clinical intervention or guideline.
What it foundGlobal prevalence of gallbladder and biliary diseases increased from 157.4 million (95% UI 134.0 to 183.3) in 1990 to 264.4 million (226.0 to 309.9) in 2023, but age-standardised rates declined from 3573.2 to 2990.1 per 100,000 population.
ContextThis literature reports a systematic analysis of the global burden of gallbladder and biliary diseases, highlighting their significant contribution to digestive disease burden across geographies, sexes, and ages.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

GBD 2023 Gallbladder and Biliary Disease Collaborators · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗Permalink

Esophagus/Reflux· 1

Esophagus/Reflux retrospective · n=91 · Nov 2, 2026 · J Gastroenterology · IF 5.7

Salvage esophagectomy versus photodynamic therapy for localized residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy or radiotherapy: a single-center comparative study.

New evidenceesophageal cancer
Clinical takeawayConsider PDT as an organ-preserving salvage option for localized residual or recurrent ESCC after CRT/RT in patients unsuitable for surgery due to advanced age, comorbidities, or limited surgical tolerance.
What it foundPDT achieved initial local complete response in 74.1% of patients compared to 94.0% R0 resection with salvage esophagectomy, with no significant difference in OS (p = 0.597) or DSS (p = 0.670).
ContextPDT demonstrated a favorable safety profile and may offer an organ-preserving salvage treatment option for carefully selected patients with localized residual or recurrent ESCC after definitive CRT or RT, particularly those unsuitable for surgery because of advanced age, substantial comorbidities, or limited surgical tolerance. This study does not establish equivalence or non-inferiority between PDT and salvage esophagectomy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ujiie N … Kamei T · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink

Pancreas/Biliary· 2

Pancreas/Biliary retrospective · n=1,018 · Nov 5, 2026 · J Hepatobil Pancreat Sci · IF 3.8

Safety of Continuing Single-Agent Antithrombotic Therapy During Emergency Cholecystectomy for Acute Cholecystitis: An Overlap-Weighted Propensity Score Analysis With the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO).

New evidencecholedocholithiasisERCPbiliary stricture
Clinical takeawayWhen adequate antithrombotic washout is not feasible, these data support proceeding with emergency cholecystectomy for acute cholecystitis on single-agent therapy; the cohort was retrospective and the primary outcome was blood loss.
What it foundIntraoperative blood loss >100 mL occurred in 25.4% on continued single-agent antithrombotic therapy vs 27.3% without (RR 0.93, 95% CI 0.69-1.26), within the prespecified margin of 1.5; perioperative bleeding complications and stay did not differ.
ContextResults were consistent in sensitivity and drug-specific subgroup analyses, including direct oral anticoagulants (1,018 patients, seven institutions).
Emergingsuggested applicable standard· EASL (European Association for the Study of the Liver), "EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones," Journal of Hepatology 2016;65(1):146-181, 2016

… For acute cholecystitis, early laparoscopic cholecystectomy preferably within 72 h of admission should be performed by surgeons with adequate expertise (high quality; strong recommendation). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Abdominal ultrasound should be performed in a patient with a recent history of biliary pain (high quality evidence; strong recommendation); in case of strong clinical suspicion of gallbladder stones and negative abdominal ultrasound, EUS (or magnetic resonance imaging) may be performed (low quality; weak). Cholecystectomy is the preferred treatment for symptomatic gallbladder stones (moderate quality; strong recommendation), and laparoscopic cholecystectomy is the standard method, including for acute calculous cholecystitis (high quality; strong), although mini-laparotomy cholecystectomy (laparotomy <8 cm) is an equally acceptable alternative (high quality; strong). For uncomplicated biliary colic, cholecystectomy should be performed as early as possible (low quality; weak recommendation); EASL qualifies that cholecystectomy may not be necessary if biliary colic has not occurred within the last 5 years or after just one episode of colic (~50% chance of another colic within 1 year). For acute cholecystitis, early laparoscopic cholecystectomy preferably within 72 h of admission should be performed by surgeons with adequate expertise (high quality; strong recommendation). Antibiotics are NOT recommended at all times in mild acute cholecystitis, i.e. without cholangitis, bacteremia/sepsis, abscess or perforation (very low quality; weak recommendation). Biliary colic should be treated with NSAIDs, e.g. diclofenac 50-75 mg IM, ketoprofen 200 mg IV, or indomethacin 50 mg IV / 2 × 75 mg suppositories (moderate quality; weak), with spasmolytics and, for severe symptoms, opioids such as buprenorphine (low quality; strong). In severe acute cholecystitis or difficult biliary anatomy, subtotal cholecystectomy (laparoscopic or open) or percutaneous cholecystostomy followed by later cholecystectomy are options; percutaneous cholecystostomy is a treatment alternative in high-risk patients, but whether definitive cholecystectomy is still needed afterwards is explicitly unsolved (no RCTs) and cholecystectomy should be considered, since patients who improve after cholecystostomy may worsen during follow-up. In the elderly and those with high anaesthetic risk, cholecystectomy should be performed for gallstone complications (acute cholecystitis, gallstone pancreatitis, obstructive jaundice) as soon as general status allows (low quality; weak), and laparoscopic cholecystectomy should not be withheld on the basis of chronological age alone (very low quality; weak). Routine treatment is NOT recommended for asymptomatic gallbladder stones (very low quality; weak recommendation). Oral bile-acid litholysis, alone or with ESWL, is not recommended (moderate quality; strong). In patients with simultaneous gallbladder and bile duct stones, early laparoscopic cholecystectomy should be performed within 72 h after preoperative ERCP for choledocholithiasis (moderate quality; strong); same-day but separate ERCP and cholecystectomy are not recommended. Before elective cholecystectomy, abdominal ultrasound confirming stones is required (moderate quality; strong) and no other routine tests are necessary; liver biochemical tests in individually selected cases (very low quality; weak). Routine intraoperative cholangiography is not supported by current evidence.

EASL (European Association for the Study of the Liver), "EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones," Journal of Hepatology 2016;65(1):146-181, 2016 · reviewed 2026-07-23 ↗
Tadokoro T … Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) · Journal of Hepato-Biliary-Pancreatic Sciences · IF 3.8 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=1,382 · Nov 4, 2026 · J Gastroenterology · IF 5.7

From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin-gemcitabine-durvalumab in advanced biliary tract cancers.

New evidencecholangiocarcinomabiliary stricturepancreatic cancer
Clinical takeawayReal-world outcomes support CGD as the first-line standard in advanced biliary tract cancer, including for patients outside TOPAZ-1 eligibility, whose survival was similar to the trial arm.
What it foundOverall survival in 1,382 real-world patients from 55 centres was longer than in the reconstructed TOPAZ-1 CGD arm (HR 0.83, p=0.012; calibrated HR 0.84); trial-eligible patients did better than the trial population (HR 0.76) and trial-ineligible patients similarly (HR 0.98).
ContextRetrospective comparison against reconstructed trial data; the larger differences for ECOG PS 0 and locally advanced disease are exploratory.
Reinforcessuggested applicable standard· NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Stage cholangiocarcinoma with multiphasic MRI/MRCP plus CT chest/abdomen/pelvis, obtain tissue via ERCP brush cytology with FISH, cholangioscopy-directed biopsy, or EUS-FNA (avoiding primary perihilar tumor sampling if liver transplant is being considered due to theoretical seeding risk), and manage through a multidisciplinary tumor board with treatment stratified by tumor location: resect (anatomic hepatectomy for intrahepatic, hemihepatectomy with bile duct resection for perihilar, Whipple for distal) with adjuvant capecitabine (category 1, per BILCAP) when resectable. For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. Selected unresectable early-stage perihilar tumors may undergo neoadjuvant chemoradiation and liver transplant per the Mayo Clinic protocol at experienced centers, and jaundice or cholangitis is managed with biliary drainage (ERCP preferred over PTC).

NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma · reviewed 2026-07-21 ↗
Camera S … Casadei-Gardini A · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink

Endoscopy· 2

Endoscopy retrospective · n=5,028 · Nov 2, 2026 · J Clin Gastro · IF 2.9

Percutaneous Endoscopic Gastrostomy Versus Image-Guided Gastrostomy Placement in Patients With Cirrhosis: A Multi-Institutional Research Network Study.

Practice-changingcirrhosishealth services
Clinical takeawayWhere both routes suit the patient, these associations favour PEG; this is a retrospective propensity-matched cohort, so the mortality difference is an association.
What it foundPEG placement in cirrhosis patients was associated with reduced 6-month mortality (aHR 0.80, 95% CI 0.70-0.91) and fewer tube replacements (aOR 0.47, 95% CI 0.36-0.63) compared to IR G-tube.
ContextProvides evidence to inform gastrostomy tube selection in cirrhosis patients.
Refinessuggested applicable standard· ASGE 2024 (Gastrointest Endosc 2025;101:25-35) / ESGE 2021 (Endoscopy 2021;53:178-195)

PEG remains the standard for durable enteral access in patients unable to swallow safely or meet nutritional needs orally, placed by the pull (Gauderer-Ponsky) technique, and ASGE 2024 now suggests PEG over IR-guided gastrostomy for initial placement in normal foregut anatomy. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

PEG remains the standard for durable enteral access in patients unable to swallow safely or meet nutritional needs orally, placed by the pull (Gauderer-Ponsky) technique, and ASGE 2024 now suggests PEG over IR-guided gastrostomy for initial placement in normal foregut anatomy. A single prophylactic IV dose of a beta-lactam antibiotic (e.g., cefazolin) is given before placement. Post-procedure bowel rest is no longer recommended: feeding may start within 3-4 hours of uncomplicated placement (ESGE 2021, strong/high-quality; ASGE 2024, strong/moderate), medications may be given immediately, and routine gastric residual volume checks are not indicated. Buried bumper prophylaxis is daily site care with DAILY inward tube mobilization and a loose external bumper kept 1-2 cm from the abdominal wall (ESGE 2021), not weekly rotation. Antiplatelet agents, including dual antiplatelet therapy, need not be routinely withheld for PEG; anticoagulant management is individualized by multidisciplinary discussion of bleeding versus thrombotic risk. In malignant dysphagia, either transoral pull PEG or direct (introducer) PEG is acceptable with counseling about implantation metastasis and periodic site examination. Device selection among PEG, PEG-J, DPEJ, surgical gastrostomy, and parenteral nutrition remains multidisciplinary, and a goals-of-care discussion before placement, including avoiding routine PEG in advanced dementia in favor of careful hand feeding (AGA 2020 / Choosing Wisely), is unchanged.

ASGE 2024 (Gastrointest Endosc 2025;101:25-35) / ESGE 2021 (Endoscopy 2021;53:178-195) · reviewed 2026-07-19 ↗
Cooper KM … Kohli DR · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy retrospective · n=492 · Nov 2, 2026 · Endoscopy · IF 11.8

Efficacy of Endoscopic Hand Suturing for Prevention of Adverse Events After Gastric Endoscopic Submucosal Dissection: A Multicenter Propensity Score-Matched Study.

New evidenceESDhemostasisendoscopy qualitycomputer-aided detection
Clinical takeawayWhere hand suturing is available, consider closing gastric ESD defects, allowing a median 52.5 minutes and a learning curve of about 25 cases; the evidence is retrospective with historical controls.
What it foundIn a retrospective propensity-matched study (123 sutured vs 369 historical and contemporaneous controls), adverse events were 1.6% vs 8.9% and delayed bleeding 1.6% vs 8.4%. Closure was complete in 94.7%, median suturing time 52.5 minutes; 27% dehisced by day 5 without more delayed bleeding.
ContextLarger absolute risk reductions in BEST-J high and very-high risk groups were exploratory.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Minoda Y … Okamura T · Endoscopy · IF 11.8 · PubMed ↗Permalink

Motility· 3

Motility prospective cohort · n=401 · Nov 5, 2026 · Clin Gastro Hep · IF 16.2

Latent Class Analysis May Predict Patients with Irritable Bowel Syndrome Who Respond to Amitriptyline: Post Hoc Analyses from ATLANTIS.

New evidenceIBSbiomarkerartificial intelligence
Clinical takeawayNo change to who is offered low-dose amitriptyline for IBS: the clusters are exploratory. Expect more discontinuation and side effects in patients with severe combined gut and psychological symptoms.
What it foundAmitriptyline reduced IBS-SSS by 103.44 vs placebo's 61.89 in patients with predominant psychological symptoms and milder gastrointestinal symptoms (cluster 3), p=0.045.
ContextLow-dose amitriptyline was superior to placebo overall in ATLANTIS; this analysis of 401 participants asked whether symptom clusters modify that.
Refinessuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnosis: use a positive diagnostic strategy based on Rome IV criteria rather than a strategy of exclusion (strong for cost-effectiveness, high quality; consensus for time-to-therapy), and categorize by IBS subtype (consensus). In patients with IBS and diarrhea symptoms: check celiac serology (strong, moderate) and, in those WITHOUT alarm features, fecal calprotectin (or fecal lactoferrin) plus CRP to rule out IBD (strong; moderate quality for CRP/calprotectin, very low for lactoferrin). Recommend AGAINST routine stool testing for enteric pathogens (conditional, low) and AGAINST routine colonoscopy in patients younger than 45 without warning signs (conditional, low). Anorectal physiology testing only when symptoms suggest a pelvic floor disorder and/or for refractory constipation not responding to standard medical therapy (consensus). Treatment, all subtypes: soluble, not insoluble, fiber (strong, moderate); a LIMITED trial of a low-FODMAP diet (conditional, very low); gut-directed psychotherapies for global symptoms (conditional, very low); TCAs for global symptoms (strong, moderate); peppermint suggested (conditional, low); antispasmodics for abdominal pain (conditional, low); AGAINST probiotics (conditional, very low), AGAINST fecal transplant (strong, very low). IBS-C: chloride channel activators (strong, moderate) and guanylate cyclase activators (strong, high); AGAINST PEG products for global IBS-C symptoms (conditional, low); tegaserod reserved for women younger than 65 with ≤1 cardiovascular risk factor who have not adequately responded to secretagogues (strong/conditional, low). IBS-D: rifaximin (strong, moderate); alosetron only for women with severe IBS-D who have failed conventional therapy (conditional, low); mixed opioid agonists/antagonists, i.e. eluxadoline (conditional, moderate); AGAINST bile acid sequestrants (conditional, very low).

American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021 · reviewed 2026-07-21 ↗
Black CJ … ATLANTIS trialists · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Motility retrospective · n=81 · Nov 1, 2026 · Neurogastro Motil · IF 3.5

Similar Tolerance of Glucagon-Like PEPTIDE-1 Agonist Therapy in Patients With Delayed and Normal Gastric Emptying.

New evidencegastroparesis
Clinical takeawayPrior delayed emptying on scintigraphy need not by itself rule out a GLP-1RA, but this retrospective series had only 14 such patients and cannot establish safety.
What it foundGI symptoms developed in 36% with delayed vs 52% with normal emptying (p=0.38); among patients who stopped the drug, GI symptoms were the reason in 3 of 8 vs 11 of 37 (p=0.70), and treatment durations were similar (318 vs 193 days, p=0.31). Injectable semaglutide was the most commonly prescribed GLP-1RA.
ContextThe authors conclude the data do not support strictly avoiding GLP-1RAs in gastroparesis; overall, 56% stopped the drug, 31% of them for GI symptoms.
Emergingsuggested applicable standard· American Gastroenterological Association (AGA), 'AGA Clinical Practice Guideline on Management of Gastroparesis', Staller K, Parkman HP, Greer KB, Leiman DA, Zhou MJ, Singh S, Camilleri M, Altayar O; AGA Clinical Guidelines Committee. Gastroenterology. 2025 Oct;169(5):828-861. doi:10.1053/j.gastro.2025.08.004. PMID 40976635 (published online 19 Sept 2025)

Decision at stakewhether to prescribe GLP-1 receptor agonists in patients with gastroparesis

… Testing should be done without confounders: hyperglycaemia and drugs that alter emptying (opioids, GLP-1 receptor agonists, prokinetics). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Scope: individuals with suspected or confirmed idiopathic or diabetic gastroparesis, including medically refractory disease. All 12 recommendations are CONDITIONAL ('suggests'), at low or very low certainty of evidence; none are strong. DIAGNOSIS (Rec 1): AGA suggests against a 2-hour (or shorter) gastric emptying study and in favour of a 4-hour study [conditional, low certainty], because patients with normal emptying at 2 hours may be reclassified as delayed at 4 hours. The 4-hour value must be measured directly at 4 hours, not mathematically derived from earlier time points. Testing should be done without confounders: hyperglycaemia and drugs that alter emptying (opioids, GLP-1 receptor agonists, prokinetics). Two meals have well-established normal values: the low-fat Tougas/EggBeaters meal (liquid egg white, bread, jam, water; 250 kcal, 2% fat) and the Mayo Clinic meal (two whole eggs, bread, skim milk; 320 kcal, 30% fat), the latter more thoroughly validated. PHARMACOTHERAPY: AGA suggests USING metoclopramide (Rec 2) and USING erythromycin (Rec 3), each conditional/very low certainty. Metoclopramide, oral tablet/liquid or intranasal, start 5 mg before meals, may increase up to 10 mg before meals; discuss potential side effects before starting (tardive dyskinesia risk noted, absolute risk low; higher risk of adverse events leading to discontinuation in older patients and those on psychotropics); assess efficacy and side effects at 4-8 weeks to decide on continuation, then monitor for the duration of therapy. Patients placing higher value on adverse-event risk and lower value on symptom improvement may reasonably decline it. Erythromycin, low dose (e.g. 100-150 mg by mouth, 30 min before meals) to reduce side effects seen at 250-500 mg; ethylsuccinate oral suspension allows smaller doses since tablets come only in high strengths; prokinetic via motilin agonism with no direct antiemetic effect; tachyphylaxis with prolonged continuous use is managed by drug holidays (e.g. 3 weeks on, 1 week off); cautions include QT prolongation, CYP3A interactions and antibiotic resistance. AGA suggests AGAINST, as first-line therapy, with shared-decision carve-outs, domperidone (Rec 4), prucalopride (Rec 5), aprepitant (Rec 6), nortriptyline (Rec 7.1) and buspirone (Rec 7.2) [conditional; low to very low certainty], and against cannabidiol EXCEPT in the context of a clinical trial (Rec 8, conditional/low certainty). Each carries an explicit shared-decision-making carve-out naming who may still reasonably use it: domperidone for patients who had neurological side effects on metoclopramide or who have movement disorders such as Parkinson's disease (US use requires an FDA expanded-access IND, and the sole US supplier is exiting; obtain baseline potassium, magnesium and ECG QTc, monitor on therapy, reassess at 4-8 weeks); prucalopride particularly in idiopathic gastroparesis (patients with diabetic or connective-tissue-disease-related gastroparesis are less likely to respond) and in those with coexisting chronic idiopathic constipation, noting the depression/suicidality monitoring warning; aprepitant for nausea and vomiting not helped by 5-HT3 antagonists such as ondansetron, recognising it has no effect on gastric motor function; nortriptyline for coexisting IBS or significant abdominal pain, started at low dose and titrated slowly, framed to patients as a peripheral neuromodulator; buspirone for predominant early satiety and bloating. For cannabidiol the panel notes the single positive trial used pharmaceutical-grade Epidiolex, which is not available for clinical use in gastroparesis, that commercial formulations are unregulated and variable in potency, and that THC-containing products raise cannabinoid hyperemesis concern. PROCEDURES (medically refractory disease): AGA suggests against G-POEM EXCEPT for selected patients with medically refractory disease (Rec 9, conditional/low certainty), candidates should have gastroparesis confirmed on an appropriately performed 4-hour gastric emptying study, generally with at least moderate delay (20% retention at 4 hours with the EggBeaters meal), at least six months of moderate cardinal symptoms (nausea, vomiting and/or postprandial fullness), and a prior trial of other treatments including a prokinetic such as metoclopramide plus an antiemetic. AGA suggests against pyloric botulinum toxin injection (Rec 11, conditional/very low certainty), noting that retreatment as often as every 3 months limits cost-effectiveness and that repeat treatment may cause pyloric scarring complicating later G-POEM; patients placing higher value on endoscopic intervention and lower value on chronic medical therapy may reasonably attempt it. AGA suggests against the ROUTINE INITIAL use of gastric electrical stimulation (Rec 12, conditional/very low certainty), reserving it, as with G-POEM, for select patients whose symptoms are refractory to medical therapy; patients placing higher value on potential nausea/vomiting improvement and lower value on the increase in serious adverse events may reasonably select GES, and should be told it aims to improve nausea and vomiting, not abdominal pain. For surgical pyloric interventions (pyloromyotomy or pyloroplasty) AGA makes NO recommendation and designates a knowledge gap, advising use only in the context of clinical trials (Rec 10). NON-GRADED adjuncts appear only as implementation considerations, not recommendations: panel content experts use small-particle, low-fat, low-residue diets before or alongside pharmacotherapy, and as-needed antiemetics (5-HT3 antagonists e.g. ondansetron, H1 antagonists e.g. promethazine, D2 antagonists e.g. prochlorperazine); efficacy of pharmacological interventions is assessed at 4-8 weeks. The guideline does NOT address exclusion of mechanical obstruction, enteral/J-tube nutrition, glycaemic targets, or perioperative GLP-1 RA management, those remain with the supporting documents.

American Gastroenterological Association (AGA), 'AGA Clinical Practice Guideline on Management of Gastroparesis', Staller K, Parkman HP, Greer KB, Leiman DA, Zhou MJ, Singh S, Camilleri M, Altayar O; AGA Clinical Guidelines Committee. Gastroenterology. 2025 Oct;169(5):828-861. doi:10.1053/j.gastro.2025.08.004. PMID 40976635 (published online 19 Sept 2025) · reviewed 2026-07-19 ↗
Rolak SC … Hasler WL · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink
Motility guideline · Nov 1, 2026 · Neurogastro Motil · IF 3.5

Diagnosis and Management of Achalasia in Children, BSPGHAN and BAPS Consensus Statement.

Guideline / reviewpediatricguidelineesophageal motilityachalasia
Clinical takeawayUse high-resolution manometry as the primary diagnostic investigation for suspected pediatric achalasia, supplemented by timed barium oesophagogram and endoscopy. Consider peroral endoscopic myotomy or laparoscopic Heller's myotomy as first-line definitive treatments, guided by achalasia subtype, center expertise, and family preference. Ensure structured transition to adult care and implement long-term surveillance.
What it foundHigh-resolution manometry is recommended as the primary diagnostic tool for pediatric achalasia, with timed barium oesophagogram and endoscopy as complementary modalities. Peroral endoscopic myotomy and laparoscopic Heller's myotomy are recommended as first-line definitive treatments.
ContextThis consensus statement fills a gap by providing the first pediatric-specific guidelines for achalasia, where previously only adult guidelines existed.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mutalib M … Papadopoulos M · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink

Colorectal· 1

Colorectal prospective cohort · n=9,523 · Nov 3, 2026 · Dis Colon Rectum · IF 3.5

Differences in Presentation and Prognosis of Early versus Late Diagnosis of Locoregional Recurrences after Colon Cancer Resection: A Nationwide Cohort Study.

New evidencecolorectal cancerepidemiology
Clinical takeawayNo clinical action recommended; further research is needed to determine if intensified surveillance improves outcomes for early locoregional recurrence.
What it foundLate diagnosis of locoregional recurrence (≥1 year) was associated with longer overall survival (median 18.0 vs 9.1 months; HR 0.83, 95% CI 0.69-0.99) and higher rates of curative intent treatment (34.6% vs 24.0%, p=0.01) compared to early diagnosis (<1 year). In patients treated with curative intent, overall survival did not differ between early and late locoregional recurrence (median 40.1 vs 40.7 months; HR 1.05, 95% CI 0.73-1.51, p=0.79).
ContextConfirms prior evidence that early recurrence (<1 year) is associated with poorer outcomes in palliative treatment, but refines understanding by showing survival is similar in curative-intent treatment regardless of timing.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Rademaker E … collaborators of the Dutch Snapshot Research Group and Dutch Complex Colon Cancer Initiative · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Everything else this week39 that cleared the bar

Ranked below the cards above, not excluded: these met the bar and were read and scored the same way. One line each, grouped by subspecialty, highest signal first; click through for the paper.

IBD· 14

Also screened this week56 papers read, not selected

These cleared the journal filter and were read, but were not selected this week. A score means the paper was weighed: below 35 it fell short of the bar; at 35 or above, a check after scoring set it aside. A blank means it was set aside before scoring. Listed for anyone going deeper; no takeaway attached, because none was written. How we choose →

IBD· 11

Hepatology· 15

Endoscopy· 16

How we choose

the same pipeline every week
01

Scan

Every new paper across 48 vetted GI, hepatology, and general-medicine journals.

02

Screen

Drop what is not a study: letters, editorials, corrections, case reports. Classify the rest.

03

Anchor

Compare each paper to the guideline standard it touches, and record how far it moves it.

04

Verify

An adversarial second pass checks every claim against its cited source.

05

Vet

Each issue is reviewed by a physician editor before it publishes.